Lake Street Capital Lowers Sensus Healthcare (NASDAQ:SRTS) Price Target to $13.00

Sensus Healthcare (NASDAQ:SRTS) had its price objective cut by equities research analysts at Lake Street Capital from $18.00 to $13.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital’s price target indicates a potential upside of 183.84% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on the company. HC Wainwright upped their target price on Sensus Healthcare from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. Maxim Group upped their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a report on Friday, November 15th.

Sensus Healthcare Trading Up 2.9 %

Shares of Sensus Healthcare stock opened at $4.58 on Tuesday. The stock has a market capitalization of $75.55 million, a price-to-earnings ratio of 11.45 and a beta of 1.28. Sensus Healthcare has a twelve month low of $3.09 and a twelve month high of $9.33. The business’s 50 day simple moving average is $6.13 and its 200-day simple moving average is $6.68.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. Sell-side analysts predict that Sensus Healthcare will post 0.32 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC grew its holdings in Sensus Healthcare by 175.5% during the fourth quarter. Squarepoint Ops LLC now owns 85,677 shares of the company’s stock valued at $593,000 after purchasing an additional 54,576 shares during the last quarter. Man Group plc boosted its holdings in shares of Sensus Healthcare by 34.0% during the 4th quarter. Man Group plc now owns 59,338 shares of the company’s stock worth $411,000 after buying an additional 15,059 shares during the period. OMERS ADMINISTRATION Corp acquired a new position in Sensus Healthcare in the 4th quarter valued at $381,000. Millennium Management LLC raised its holdings in Sensus Healthcare by 256.6% in the 4th quarter. Millennium Management LLC now owns 85,329 shares of the company’s stock worth $590,000 after acquiring an additional 61,403 shares during the period. Finally, BNP Paribas Financial Markets acquired a new position in Sensus Healthcare during the 4th quarter worth $47,000. Institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.